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Abstract. Currently, there is no single test for multiple sclerosis (MS). Diagnosis is confirmed through clinical evaluation,
abnormalities revealed by magnetic resonance imaging (MRI), and analysis of cerebrospinal fluid (CSF) chemistry. The early
and accurate diagnosis of the disease, monitoring of progression, and gauging of therapeutic intervention are important but
elusive elements of patient care. Moreover, a deeper understanding of the disease pathology is needed, including discovery of
accurate biomarkers for MS. Herein we review putative biomarkers of MS relating to neurodegeneration and contributions to
neuropathology, with particular focus on autoimmunity. In addition, novel assessments of biomarkers not driven by hypotheses
are discussed, featuring our application of advanced proteomics and metabolomics for comprehensive phenotyping of CSF and
blood. This strategy allows comparison of component expression levels in CSF and serum between MS and control groups.
Examination of these preliminary data suggests that several CSF proteins in MS are differentially expressed, and thus, represent
putative biomarkers deserving of further evaluation.
1. Introduction
This article will briefly review our current knowledge
of biomarkers in multiple sclerosis (MS), with particu-
lar focus on neuroimmunology, and especially antibod-
ies. It is not intended as an exhaustive review, as such
work has recently been completed in several excellent
and thorough publications [1–3]. The later part of the
manuscript will focus on the appraisal of groundwork
biomarker discovery in MS using our own novel strat-
egy, which allows detection, identification, and quan-
tification of a large number of putative biomarkers in
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MS, leading to a “molecular signature” of proteomic
patterns free of pre facto bias.
2. Multiple sclerosis
MS, the most common autoimmune disease involv-
ing the nervous system (CNS), is a chronic illness af-
fecting CNS pathways and leading to progressive neu-
rological dysfunction [4,5]. The disease affects twice as
many women as it does men. Approximately 400,000
Americans acknowledge having MS, and every week
about 200 people are diagnosed. Worldwide, MS may
affect 2.5 million individuals. The high economic bur-
den is reflected in the total estimated annual cost for
all people with MS in the United States: more than
$9 billion dollars [6]. Both genetic and environmental
factors contribute to MS susceptibility. High-risk re-
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gions include the northern United States and the Scan-
dinavian countries, while Japan and Africa are areas of
lower risk. Individuals that migrate from high-risk to
low-risk regions carry their native risk for contracting
MS, suggesting that exposure to an environmental fac-
tor contributes to susceptibility. Genetic studies have
shown that the risk of developing MS is elevated 10-
to 20-fold in first-degree relatives of individuals with
MS and that the concordance rate among monozygotic
twins is 30%–35%, but only 2%–5% in dizygotic twins.
Clinically, the disease can be broadly divided into
a relapsing-remitting form characterized by a series
of exacerbations that result in varying degrees of dis-
ability from which the patient recovers, and two pro-
gressive forms (secondary progressive, SP and primary
progressive, PP) in which the patient does not expe-
rience exacerbations, but instead experiences a grad-
ual decline. Though a relapsing-remitting onset is ob-
served in 85–90% of all patients, the course of the dis-
ease in about 40% of them ultimately becomes pro-
gressive [5]. Thus, the current prevalence of the sub-
types is approximately 45% RR, 35% SP, and 20% PP.
The pathological hallmark of MS is the demyelinated
plaque found throughout the brain and spinal cord, with
CNS perivascular infiltration of inflammatory cells, de-
myelination, astrogliosis, and axonal injury (reviewed
in references [7–10]). Symptoms are believed to re-
sult primarily from axonal demyelination that inhibits
or blocks conduction. Amelioration of symptoms has
been attributed to both partial remyelination and reso-
lution of inflammation.
It is widely accepted that MS is a complex syn-
drome and may not represent a single disease entity.
Based on accumulating data from immunological stud-
ies of patients with MS and a wealth of animal model
data, autoimmune dysregulation has been viewed as the
major contributor to tissue damage (reviewed in ref-
erences [9–11]. There is widespread support for the
view that MS is an immune-mediated disease, based
largely on: 1) the genetic linkage to immune-related
molecules, primarily MHC class II; 2) the presence of
CNS inflammatory infiltrates including CD4+ T cells,
CD8+T cells, B cells, plasma cells, macrophages; 3)
magnetic resonance imaging (MRI) indicative of the
loss of integrity of the blood – brain barrier (BBB); 4)
the response to immune-modulating therapies; 5) sim-
ilarities to the animal model of experimental autoim-
mune encephalomyelitis (EAE); and 6) the presence of
oligoclonal bands and elevated immunoglobulin levels
in the cerebrospinal fluid (CSF).
In accordance with this evidence, a widely accepted
model of MS immunopathology [12] suggests that ac-
tivated autoreactive T cells recognize myelin antigens
in the periphery, cross the CNS endothelium, leading
to a cascade of events that culminates in white matter
inflammation and tissue destruction. Inside the CNS,
release of local cytokines, chemokines, and matrix
metallo-proteins support the recruitment of subsequent
waves of infiltrating effector cells (including mono-
cytes) and B cells. Mechanisms of myelin destruc-
tion and axonal damage are likely to be multiple and
include direct effects of pro-inflammatory cytokines,
complement-fixing antibodies, antigen-specific and
non-specific cytotoxicity, and apoptosis.
While it is broadly appreciated that a sizeable per-
centage of MS cases involve immune-mediated patho-
genesis, neurodegenerative processes not necessarily
associated with inflammation appear to be principal in
others. Theories that overlook inflammation as a pri-
mary event hold that MS is at least partially a genet-
ically determined disorder characterized by metabolic
neurodegeneration. Studies of the mechanisms of ax-
onal damage and neurodegeneration in MS are still in
their infancy, though recognition of axonal damage as
a prominent pathological feature in MS lesions is in-
creasing (reviewed in references [7,13–15]).
It is likely that both neurodegeneration and inflam-
mation contribute to various extents, both among and
within individuals with MS. In a seminal work un-
derscoring the significance of both inflammatory and
non-inflammatory mechanisms in MS pathology, Lass-
man and colleagues [16] catalogued lesions and demon-
strated the existence of four fundamentally different
patterns of demyelination in humans. While two pat-
terns (I and II) showed close similarities to T-cell-
mediated or T-cell plus antibody-mediated autoimmune
encephalomyelitis, the other patterns (III and IV) were
highly suggestive of a primary oligodendrocyte dystro-
phy, reminiscent of demyelination induced by a virus
or toxin rather than one involving the immune system.
3. Biomarkers
Biomarkers are anatomic, physiologic, biochemi-
cal, or molecular parameters associated with the pres-
ence and severity of specific disease states. Biomark-
ers are measurable by a variety of methods includ-
ing physical examination, laboratory assays, and med-
ical imaging. The hallmark of a useful biomarker
is that the state of health or disease of an individ-
ual can be accurately characterized by appraisal of the
marker [17]. Thus, biomarkers can indicate either nor-
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mal biological/pathogenic processes or pharmacolog-
ical responses to a therapeutic intervention. Simple
examples include CD4+ T-cell count in HIV-infected
patients and HDL/LDL ratios for patients with hyper-
cholesterolemia. Some biomarkers are not specific;
prostate-specific antigen (PSA) may be increased not
only in men who have prostate cancer, but also in those
with benign prostatic hyperplasia or a prostate infec-
tion. More pertinent to the present report, white matter
abnormalities, which can be detected by MRI, serve as
biomarkers for MS.
4. Biomarkers in MS inflammation
The current inventory of prospective MS biomarkers
by and large includes those that reflect the changeable
inflammatory processes in the majority of cases. Many
such biomarkers are found in the periphery, namely in
the serum. However, analysis of CSF can add greater
pathologic specificity, as it is most closely associated
with the disease process. Thus, considerable efforts
have been made to identify prognostic and diagnostic
markers in the CSF from patients with MS.
The biomarkers reflecting the role of inflammation
include cytokines, chemokines, adhesion molecules,
and each of their respective receptors, complement,
and antibodies. Specifically, the pro-inflammatory cy-
tokines associated with T cells; interferon (IFN)-γ, tu-
mor necrosis factor (TGF)-α and IL-12 may be ex-
pressed at elevated levels. Correspondingly, the anti-
inflammatory cytokines such as IL-4, IL-10, and TGF-
β may be overexpressed during periods of remission.
In each of these cases, more evidence is required.
Breakdown of the blood-brain barrier (BBB) is nec-
essary in some cases before immune effector cells can
extravasate into the CNS. In other cases T cells can ex-
travasate through an intact BBB. Disruption of the BBB
involves proteolytic activity of enzymes that degrade
the extracellular matrix (ECM), chief among which are
the matrix metalloproteinases (MMPs). Accordingly,
elevated expression levels of MMP family members in
patients with MS have been reported.
In addition to larger proteins, small-molecule
biomarkers have also been investigated. For instance,
it is appreciated that nitric oxide (NO) is formed in
inflammatory disorders. Consequently, levels of NO,
its oxidation products (NOx), and the iNOS enzyme
are altered. Several studies have examined particular
parts of this response. CSF nitrite levels appear to
be correlated with disease exacerbation and concurrent
inflammation in the CNS of patients with MS [18].
It is well-accepted that autoantibodies toward insulin
and DNA are established biomarkers in the autoim-
mune diseases type 1 diabetes (T1D) and systemic lu-
pus erythematosus, respectively. However, these au-
toantibodies have yet to be implicated directly in dis-
ease pathogenesis. In contrast, myasthenia gravis au-
toantibodies directed toward components of the neuro-
muscular junction are both diagnostic biomarkers and
participants in disease pathology [19]. Neuromyelitis
optica, (NMO) also termed Devic’s syndrome, is an in-
flammatory demyelinating disease that affects the optic
nerves and spinal cord, but unlike MS, does not affect
the brain. Early in its course, Devic’s is difficult to dis-
tinguish from MS, yet the distinction remains impor-
tant, as treatment and prognosis of these two diseases
are dissimilar. The presence of IgG serves as a specific
serologic biomarker for early diagnosis of NMO and
distinction from MS [20]. The NMO serum IgG re-
veals a characteristic pattern upon immunohistochem-
ical staining of mouse CNS tissue. Similarly, Vincent
and colleagues [21] found that the serum Ig of patients
with MS recognized antigens on the surface of CNS-
derived cells, whereas serum Ig from controls did not.
In this case, as with NMO, the appropriate next step
in biomarker refinement would be identification of the
target(s).
As autoantibodies have been shown to be use-
ful markers in some autoimmune diseases, these
molecules have also been examined for their suitability
as biomarkers in MS. Other approaches have focused
on individual candidate antigens. Consequently, there
is an abundance of reports concerning autoantibodies
in MS. Although much of this work has focused on
the role of autoantibodies in the immunopathogenesis
of MS, most are still only putative biomarkers, as a
direct role in pathology has not been reported. That
said, no study has clearly demonstrated that autoanti-
bodies in MS are either reliable biomarkers or contrib-
utors to the disease pathology. However, when consid-
ered collectively, the reports on EAE and MS certainly
indicate that suspicion of such a role for autoantibod-
ies is likely well-founded. The evidence for a conse-
quential humoral response within patients with MS in-
cludes the presence of CSF oligoclonal bands [22] and
intrathecal immunoglobulin synthesis [23], both hall-
marks of MS and diagnostic biomarkers used in con-
junction with clinical presentation and MRI. This com-
bination of several biomarkers is necessary, because
CSF oligoclonal bands and evidence of intrathecal im-
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munoglobulin synthesis are found in conditions other
than MS, such as subacute sclerosising panencephali-
tis (SSPE). Again, this underscores the dictum that no
single biomarker is likely to be conclusive, but rather
an arrangement of at least several biomarkers, form-
ing a profile or fingerprint, will be needed to provide
valuable information.
The possibility that CSF Ig in patients with MS
is generated as a response to myelin self-antigens
has also been investigated in detail. Antibodies spe-
cific for MBP have been identified in the CSF [24–
26]. Autoantibodies reactive with myelin-associated
glycoprotein (MAG) [27], the enzyme transaldoase
(TAL) [28], MOG [29], and oligodendrocyte-specific
protein (OSP) [30] have also been detected in the
CSF of a subset of patients with MS. One series of
reports [31] demonstrated that individuals with MS
who have intrathecal synthesis of IgM were likely to
progress from RRMS to a more severe progressive
form. The presence of intrathecal IgM correlates with
progression from initial stages to clinically definite
MS [32]; higher EDSS scores [33] and a fraction of
this IgM reactive with myelin lipids suggests a more
aggressive course [34].
Serum anti-MBP antibodies have been reported [35,
36], though not in all studies [37–39]. As with MBP,
reports are conflicting regarding the detection of anti-
MOG antibodies in MS serum [29,40]. There are re-
ports detecting serum autoantibodies against recombi-
nant TAL [28], and B cells secreting autoantibodies di-
rected against PLP have been identified in the periph-
eral blood of patients with MS [41]. Autoantibodies to
other putative MS antigens, such as MOBP, CNPase,
αß-crystalline, and S100B have not been analyzed in
sera [42].
Autoantibodies directed against non-myelin antigens
have also been detected in the sera of some patients
with MS. Anti-nuclear antibodies (ANA) [43], anti-
cardiolipin antibodies [44], and antibodies against beta-
2-glycoprotein I [45] are detected in MS sera more
frequently than in normal subjects. Recently, elevated
levels of antibodies towards a large panel of organ- and
non-organ-specific antigens were reported in patients
with MS relative to controls [46]. Currently, no B-cell
antigen specific for MS or identifying a subtype of MS
has been established as a true biomarker for MS.
Our own studies have indicated that the antibodies
to chief candidate myelin antigens, MBP and MOG, in
the serum and CSF of patients with MS, are not readily
detectable [47,48] and therefore fail as useful biomark-
ers. Our work has shown that patients with acute dis-
seminated encephalomyelitis (ADEM), an induced en-
cephalomyelitis, have these autoantibodies. Moreover,
reports concerning their detection in ADEM are con-
sistent [47,49], which cannot be said of those concern-
ing MS. Our view is that the inconsistency in the re-
ported data of autoantibodies in MS is caused by false
positives generated by acute-phase reactants that result
in “sticky” antibodies. Alternatively, the difficulty in
consistently detecting autoantibodies in the periphery
of patients with MS is that they may be produced lo-
cally within the CNS at the site of injury. The evidence
for a significant humoral response within the CNS of
patients with MS includes the presence of plasma cells
and IgG in CNS lesions [16,50]. That an antigen-driven
response is at work is indicated in analysis of the im-
munoglobulinVH and VL domains from CNS samples,
which reveals that these gene segments have accumu-
lated replacement mutations in the complementary de-
termining regions (CDRs) [51] and a skewed variable
region repertoire [51,52]. These findings strongly sug-
gest an antigen-driven response, rather than polyclonal
B cell activation [53–55]. Moreover, autoantibodies to
MOG were found to be bound to disintegrating myelin
segments in MS lesions [56] and in IgG eluates from
MS lesions [48], supporting the contention that myelin
autoantibodies may mediate CNS tissue damage. IgG
isolated from CNS tissue binds to MBP in solid-phase
assays [57]. Collectively, these results support the hy-
pothesis that pathologically significant antibodies are
produced within the brain and may constitute specific
biomarkers. Measurement of these potentially useful
biomarkers is clearly limited by our current technology.
Application of novel non-invasive technology or more
sensitive assays for measurement in the periphery may
provide access to these prospective biomarkers.
5. Biomarkers in MS neurodegeneration
The neuropathologyof MS largely concerns the CNS
white matter, although lesions may sometimes be found
in the gray matter as well. The key cellular components
of the white matter are the myelin-coated axons respon-
sible for conducting nerve impulses. The remaining
fundamental CNS support cells are categorized as glial
cells and include: oligodendrocytes, which provide and
maintain the axonal myelin sheaths; astrocytes, which
provide mechanical and metabolic support; and mi-
croglia, which perform phagocytosis, essentially be-
coming activated to clean up after cell damage or death.
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The gray matter is largely comprised of neurons that
collect, integrate, and transmit information.
Certain traditional concepts regarding MS pathogen-
esis have recently come into question. For instance, it
is now evident that the types of cells and molecules in-
volved in MS are more diverse than previously thought.
In particular, some CNS lesions can include either ex-
tensive oligodendrocyte apoptosis, microglial activa-
tion, axonal damage, or all of these features, while
containing few or no lymphocytes [58]. While these
observations do not preclude the role of inflammatory
demyelination in MS pathogenesis, this form of CNS
tissue damage may predate the inflammatory lesions.
Thus, independent axonal pathology may contribute to
the primary pathobiology of the disease.
Thus, there has been a renewed interest in the neu-
rodegenerative mechanisms of MS. The most reported
tissue injury is oligodendrocyte apoptosis and axonal
degeneration and transection. Thus, irreversible neuro-
logic disability in MS is related, in part, to axonal dam-
age. All these pathological findings can be detected on
MRI as atrophy and hypointense T1-weighted lesions,
but pathogenic specificity is lacking.
Evaluation of glial cell responses in CSF and lesion
tissue [59] revealed that S100B is a worthy marker for
the relapsing phase of the disease and can be used along
with ferritin to discriminate among the types of MS.
Glial-fibrillary acidic protein (GFAP) correlated with
disability scales. In another bona fide demonstration
of the importance of combinations of biomarkers, the
S100B: ferritin ratio discriminated patients with RR
multiple sclerosis from SP, PP, or control patients and
may therefore provide a marker for irreversible damage.
Markers of tissue destruction are useful for gaug-
ing neurodegenerative processes in MS. Isoprostanes,
formed by free radical peroxidation, are emerging as
a new class of sensitive, specific, and reliable markers
of free radical damage and lipid peroxidation. CSF
levels of isoprostane are elevated in MS patients [60];
however, in this context the elevation is related to de-
generative rather than inflammatory phenomena [61].
Magnetic resonance spectroscopy can be used to detect
levels of whole brain N-acetylaspartate (NAA); the de-
creases seen in MS suggest progressive neuronal cell
loss. Though whole-brain NAA measurement offers a
quick, highly reproducible measure of disease progres-
sion, its use is dependent upon access to MRI instru-
mentation.
Some putative markers that deserve further investiga-
tion and validation include cytoskeleton structural pro-
teins like actin, tubulin, L-neurofilaments and tau pro-
tein, axon-specific antibodies, other neuronal or glial
proteins like S-100, 14-3-3 and glial fibrillary acid pro-
tein, neuronal specific enolase, and nitric oxide and
its metabolites (reviewed in reference [62]). However,
none currently fulfils the criterion of applicability in
clinical practice.
Transected or injured axons release several molecules
from their proximal extremity into the intercellular
space. Both the neurofilaments contained in the cyto-
plasm of neurons and the autoantibodies directed to-
ward them have been viewed as potential biomarkers
in MS and other neurological disorders [63]. Inves-
tigators have searched for correlations between levels
of these markers and clinical or MRI measures with
success, albeit limited.
6. Biomarkers in MS: Proteomics, the next
generation technology
Despite tremendous efforts in MS research, the spe-
cific targets of the immune response, the precise mecha-
nism for neuronal loss, and the events leading to disease
etiology are not yet clear. Better biological markers
that represent the biological activity of the disease pro-
cess and response to therapy are needed. Although nu-
merous putative MS-specific biomarkers, representing
different mechanisms of pathogenesis and steps along
the inflammatory cascade have been proposed., none
has been fully validated. As one can deduce from the
descriptions of biomarkers above, most of this work has
been limited to investigation of one to several markers
at a time. Although many advances have been made,
we are still faced with exploring complex systems with
studies designed to illuminate only one or a few of
these multi-level biological problems. Comprehensive
proteomic phenotyping fills the unmet need for rapid
and methodical examination of molecules not only in
the immune system but also from the targeted organs.
To comprehend a disease as enigmatic and heteroge-
neous as MS, a high throughput technology capable of
profiling multiple changes is needed.
We have taken a high-throughput multiplexed pro-
teomics and metabolomics approach to biomarker iden-
tification, using both discovery-based and hypothesis-
based strategies [64–66]. Biological samples are an-
alyzed by mass spectrometry because of its high sen-
sitivity, information content, and throughput. Our ap-
proach does not require any a priori assumptions about
the specific differences between sample groups. More-
over, recently developed software and bioinformatics
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infrastructure enable the comparison of large numbers
of samples in a single study. Comparison of multiple bi-
ological samples relies on the linearity of signal versus
molecular concentration, reproducibility of sample pro-
cessing, and overall spectral intensity normalization.
Thousands of molecular components can be tracked
from hundreds of samples with this approach [67–69].
Mass spectrometry measures the mass-to-charge (m/z)
ratio of proteins, peptides, nucleic acids, carbohydrates,
or metabolites. The measurements are carried out in
the gas phase on ionized analytes. The instrument con-
sists of an ion source, a mass analyzer that measures
the mass-to-charge ratio (m/z) of the ionized analytes,
and a detector that registers the number of ions at each
m/z value. Details of the various techniques, with
particular focus on proteomics, have been comprehen-
sively reviewed [70]. Electrospray ionization (ESI) is
our preferred method for quantitative differential profil-
ing. ESI is very stabile and enables direct on-line cou-
pling of liquid chromatography to mass spectrometry
by spraying the eluent into the mass spectrometer un-
der high voltage and charging conditions. The micro-
droplets formed evaporate, leaving ionized analytes for
mass analysis.
7. Biomarkers in MS: Proteomics, results
Our method for differential profiling of proteins and
low molecular weight molecules from biological sam-
ples has three main technical components: 1) sam-
ple preparation, 2) liquid chromatography-mass spec-
trometry instrumentation, and 3) data processing infor-
matics [65,67,69]. The overall separation and analy-
sis scheme is shown in Fig. 1. Initial sample prepa-
ration, prior to chromatography, varies with the bio-
logical sample, such as serum, CSF, urine, or cells;
whereas the instrumentation and software generally ap-
ply across sample types. The sample is divided into
a fraction with high molecular weight (proteome) and
another with low molecular weight (metabolome, in-
cluding free-floating peptides), since these require dif-
ferent methods of preparation, mass spectrometry and
identification. Here we focus on the proteome. High-
abundance proteins, e.g., albumin and immunoglobu-
lin, which account for about 90% of the serum pro-
teins, are removed to enable better monitoring of lower-
abundance proteins. The proteome is denatured, re-
duced, alkylated, and trypsin-digested to generate pep-
tides, which are easier to resolve than large intact
proteins. This approach enhances reproducibility and
identification. The digested sample is then applied to
on-line reverse-phase liquid chromatography, directly
coupled to electrospray ionization mass spectrometry
with time-of-flight (TOF) detection. TOF detection is
ideal for distinguishing individual components in com-
plex mixtures, since it provides high resolution and
high mass accuracy, to an optimum of 2 mDa.
An important technical advance for the mass spec-
trometry platform was the development of software to
pick peaks and make comparisons across a large num-
ber of different samples [67,71,72]. The data process-
ing includes 1) removing and smoothing of baseline
noise and spikes from the raw data, 2) dynamic thresh-
olding to select peaks in different regions of the spec-
trum, 3) considering both the m/z and chromatographic
dimensions to eliminate chemical noise and identify
peaks pertaining to true analyte molecular ions, 4) ad-
justing for small deviations in the elution time with
dynamic time warping algorithms, and 5) comparing
each file to a reference file to generate a single constant
based on the median of the ratios of intensities for all
components between the reference and test files and
normalizing the complete data set. De-isotoped peaks
at a certain frequency (e.g. one out of four samples in
a two-group cross-sectional comparison) are retained
in a merged peak list for statistical evaluation. Data
on system performance, including reproducibility and
linearity of the response, can be found in Wang et al.
and Roy et al. [67,68]. One-dimensional chromatog-
raphy with a hydrophobic reverse-phase column cur-
rently tracks more than 45,000 molecular components
in the serum proteome. More molecular components
can be monitored if the sample is separated using two
orthogonal chromatography methods. As outlined in
Fig. 1 on the right, we use strong cation exchange,
with collection of up to eight fractions, followed by the
same reverse-phase chromatography used in the one-
dimensional method. This enables tracking of about
30,000 molecular species [69].
Separating the differential profiling steps from pep-
tide identification is an extremely useful strategy for im-
proving throughput and reproducibility. Peptide iden-
tification is made using established tandem mass spec-
trometry approaches (MS/MS). Collisional activation
for tandem mass spectrometry provides fragments (usu-
ally broken at the peptide bond) that can be assigned
using a match to large public databases via the SE-
QUEST and MASCOT computer programs [73]. For
new studies, links are first made to our library of iden-
tified peptides based on retention time and mass. Addi-
tional significant differences between groups (such as
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Fig. 1. Schematic diagram of the sample preparation and mass spectrometry analysis. Biological samples can be processed through the
mass spectrometry procedures shown here. For serum, > 6,000 molecular species can now be tracked with the metabolomic and proteomic
one-dimensional approaches using current MassViewTM software. The two-dimensional approach, with a strong cation exchange (SCX)
separation before the reverse-phase HPLC, allows more than 30,000 molecular species to be tracked. Identification is done separately from the
profiling. This enables higher throughput processing and allows identification to be focused on components with the greatest difference between
the groups. Once a molecular ion is identified, the information is listed in the database for reference in future analysis.
cases of MS and healthy subjects) are considered based
on p-values and magnitudes of differences and then
identified with directed tandem mass spectrometry.
To address our first goal of serum profiling, we col-
lected serum from 20 patients with relapsing-remitting
MS and 20 normal controls. A diagnosis of MS was
confirmed based on the criteria of McDonald [74].
Serum was fractioned into the metabolome and pro-
teome and processed as described above with one-
dimensional chromatographic separation. We also ex-
tended the analysis to the examination of CSF. In MS, it
is expected that CSF more closely reflects events in the
CNS than does peripheral blood and hence is the pre-
ferred compartment for initiation of biomarker discov-
ery efforts, despite being more difficult to obtain. Al-
though most proteins (∼ 80%) in the normal CSF orig-
inate from the blood, they are generally reduced 100-
to 1,000-fold. Blood proteins passively diffuse across
capillary walls into the brain, extracellular fluid, and
CSF. Larger molecules exchange more slowly and have
a larger concentration gradient from serum to CSF than
smaller molecules. Some relative concentrations of
CSF to serum are IgM 0.0003, IgG 0.002, and albumin
0.005) [75]. Brain-derived proteins fall into three cate-
gories: 1) Proteins derived from neurons and glial cells
like tau, S-100, and neuron-specific enolase, which are
released into the ventricular and cisternal CSF, where
they have concentrations of 10-, 18-, and 1-fold higher
than found in serum, respectively. 2) Proteins derived
primarily from the leptomeninges surrounding the brain
and spinal cord that are released into the CSF, like beta
trace protein (prostaglandin-D-synthase) and cystatin
C, which are found at levels 30 and 5 times higher in
CSF than serum, respectively; and 3) brain-derivedpro-
teins that also have a blood-derived fraction in the CSF,
like transthyretin, angiotensin-converting enzyme, and
s-ICAM, which typically have lower relative concen-
trations in the CSF compared to serum (0.05, 0.01,
and 0.005, respectively). In neurological diseases with
blood-CSF barrier impairment, all blood proteins are
elevated in the CSF.
We collected CSF from 13 patients with MS and 13
control patients, all scheduled to undergo lumbar punc-
ture for medical reasons. A diagnosis of MS was con-
firmed based on the criteria of McDonald [74]. The
control CSF samples were from subjects with a variety
of conditions; only subjects with a negative CSF diag-
nosis were chosen for this study. CSF was processed
in a method similar to that described above; however,
about 100 times more CSF volume (0.5 mL) was used
than serum in order to load the same amount of pro-
tein (20µg) into the liquid chromatography-mass spec-
trometry instrument.
220 K.C. O’Connor et al. / Comprehensive phenotyping in multiple sclerosis
Table 1
Summary Statistics for Proteomic profiling of Serum and CSF
Serum CSF
Control MS Control MS
Samples 20 20 13 13
Components 7308 4162
Median CV 27 28 40 35
Number of significant changes
P < 0.001 6 13
P < 0.01 63 120
P < 0.05 313 400
Proteomic differences between MS and control sub-
jects were found in both the CSF and serum. Sum-
mary statistics on the proteomic results are provided in
Table 1. The serum samples tracked 1.8 times more
molecular components than the CSF samples (7000 vs
4000 components). The median CVs were lower for
the serum samples (28% for MS and 27% for controls)
than the CSF samples (35% for MS and 40% for the
controls). The larger CVs for the CSF are likely to re-
flect greater variation in sample collection and greater
variation in the clinical status of the control CSF group.
The number of significant changes for the control vs
MS group comparisons are presented for each sample
type and ranked by p-value. There are multiple com-
parisons in this study, and more significance should be
attached to differences with lower p-values. There were
about twice as many differences between the MS and
control groups at p-value levels < 0.01 for CSF than
serum. This difference is most significant given both
the smaller number of samples and the smaller num-
ber of components tracked for CSF. The result strongly
supports the hypothesis that CSF is a better source than
serum for initial identification of potential biomarkers
for MS.
Differential profiling for CSF is presented as a heat
map in Fig. 2. The MS and control groups can be read-
ily distinguished by the pattern of expression. The plot
shows the relative intensity for components (rows) with
p-values < 0.05 for every subject (columns). Results
are sorted by effect size, which is the mean difference
between the two groups, divided by the weighted stan-
dard deviation of the groups. In addition to between-
group differences, individual profiles (columns) can be
identified in both the MS and control groups, suggest-
ing biological heterogeneity among the subjects within
the groups.
As expected, many proteins are found in abundance
in serum, and some of these are differentially expressed
in MS subjects. Identified proteins come from a va-
riety of biological processes, including inflammation,
the complement cascade, lipoproteins and acute phase
Fig. 2. Proteome Difference Map for CSF comparison. Differences
with a p-value < 0.5 are shown for the MS vs. Control comparison.
Each column represents one subject and each row represents one
molecular component. Relative value is a normalized z score (Xi-
Xave/SD), where Xi is the intensity for sample i, Xave is the average
intensity, and SD is the weighted standard deviation. Values are
sorted by effect size, the mean difference between the two groups,
divided by the weighted standard deviation of the groups. Here, a
positive effect size indicates higher means for the MS group.
reactants. This last group of molecules is of particu-
lar interest. The acute phase response is a physiologic
reaction occurring soon after the onset of infection,
trauma, or inflammatory processes. The most promi-
nent change is a dramatic increase of acute phase pro-
teins, which are any of the non-antibody proteins found
in increased amounts in serum during this reaction; ex-
amples include C-reactive protein, serum amyloid A
protein, fibrinogen and 1-acid glycoprotein. The con-
centrations of many of the proteins within this collec-
tion have been reported to be altered in MS.
At this point, about 15% of the components in the
data set have been identified. Some of the specific
differences between MS and control subjects are pre-
sented in Fig. 3. The x-axis plots the effect size. Most
of the proteins present in Fig. 3 are tracked with more
than one peptide, as indicated in the parentheses. This
consistency increases our confidence in individual pro-
tein results. An example of this is seen in the con-
sistent results for leucine-rich alpha-2-glycoprotein in
serum, with three different peptides shown. Several
of the components presented, such as A2GP1 and hap-
toglobin, are acute phase reactants that could be as-
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Fig. 3. Proteomic differences between MS subjects and controls. The effect size, the mean difference between the two groups, divided by the
weighted standard deviation of the groups, is shown for a subset of identified components with p < 0.05. The direction of the triangle symbols
are () higher in controls, () lower in controls. Numbers in parentheses are the consistent components for that protein with p < 0.05.
sociated with inflammatory conditions. Some other
acute phase reactants, like alpha-1antitrypsin, were not
significantly elevated in serum.
The effect sizes shown in Fig. 3 are quite substantial,
with several greater than one. For reference, in another
neurological disorder, Tau and Aβ peptide have an ef-
fect size of about one in Alzheimer’s disease vs either
age-matched healthy controls or age-matched demen-
tia controls. Our calculation is based on data from
Mulder et al and references therein [76]. We have also
completed a proteomic analysis of serum samples from
rheumatoid arthritis subjects with active disease (ten-
der/swollen joints, elevated erythrocyte sedimentation
rate, etc) and controls [65]. A broader constellation of
markers consistent with a chronic inflammatory con-
dition was observed in the rheumatoid arthritis study.
Many have effect sizes greater than one. The relapsing-
remitting MS subjects in the current study do not nec-
essarily have active clinical events.
Many of the proteins identified in serum are also de-
tected in the CSF. These include alpha-1-antitrypsin,
alpha-1-acid glycoprotein, haptoglobin, transferrin,
and transthyretin. Interestingly, studies that have as-
sociated these molecules with MS have been reported:
Proteases and their inhibitors have been implicated in
the pathogenesis of MS. Levels of the protease in-
hibitor, alpha-1-antitrypsin, in the CSF have been as-
sociated with disturbances in the BBB [77]. The
acute phase protein, alpha-1-acid glycoprotein (oroso-
mucoid) levels are altered in the CSF of patients with
MS [78]. Although the function of alpha-1-acid gly-
coprotein is unknown, it has protective effects in sev-
eral in vivo models of inflammation [79]. Haptoglobin
irreversibly binds free hemoglobin to facilitate its re-
moval and increased synthesis of haptoglobin is ob-
served in conditions of extensive tissue damage and
necrosis. Its altered levels have been observed in in-
flammatory neurological diseases [80]. Studies indi-
cate that free radicals participate in the pathogenesis of
MS, and iron has been implicated as the catalyst lead-
ing to their formation. Thus, proteins involved with
iron metabolism, such as transferrin, have been pro-
posed as putative biomarkers for demyelination [81].
Finally, the level of transthyretin, a choroid plexus-
specific transport protein, has been reported to be ele-
vated, decreased and unaffected in the CSF of patients
with MS [82]. Our finding that it is elevated relative to
the non-MS group underscores our belief that many of
these potential markers warrant re-evaluation with new
and more sensitive assays.
We also identified several proteins produced in the
central nervous system. These include beta trace pro-
tein (prostaglandin-D-synthase)and cystatin C (gamma
trace), which are produced by the cells of the cerebral
cortex and choroid plexus, and transthyretin, which
is synthesized both by the choroid plexus and by the
liver. Acute phase proteins e.g. alpha-1-antitrypsin,
alpha-1-acid glycoprotein haptoglobin, and transferrin
show stronger and more consistent effects in the CSF
than serum. Often more consistent peptides per protein
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Fig. 4. Distributions for CSF proteomic differences between MS subjects and controls. Results are shown for representative peptides for
chromogranin B (effect size = 1.1, p = 0.15, 2 identified components), neurotrimin (effect size = 1.2, p = 0.0047, 2 identified components),
and transthyretin (effect size = 1.7, p = 0.00042, 22 identified components). Box and whisker plots: bottom line = 10th %, bottom box = 25th
%, center line = median, top box = 75th %, top line = 90th %, circles are individual points outside the range. Grey = MS, White = control.
are different in the CSF. Among proteins produced in
the brain, gamma trace (cystatin C), neurotrimin, chro-
mogranin B, and transthyretin are significantly differ-
ent between the MS and control groups. Distributions
for representative peptides from three of these proteins
identified in CSF are presented as box and whisker plots
in Fig. 4. All have effect sizes greater than one, which
corresponds to the boxes of the MS and control groups
being almost separated. The displayed proteins are of
neurological interest. Chromogranin B (secretonin 1),
a neuroendocrine secretory granule protein produced
in the brain and pancreas, is more abundant in the CSF
of MS subjects. The single study we found, reported
that the CSF levels of both chromogranin A and B are
similar among MS and controls groups [83], empha-
sizing again that further investigation is required. Neu-
rotrimin, a neural cell adhesion molecule produced in
the brain as well as muscle, liver, and other tissues, is
found at lower levels in the CSF in MS subjects. In-
terestingly, this protein has been implicated, in part,
in regulating the development of neuronal projections
and axonal fasciculation [84,85]. Transthyretin (preal-
bumin), which probably transports thyroxine from the
bloodstream to the brain, is elevated in the CSF of MS
subjects. All three proteins have potential connections
to MS disease physiology and require more extensive
evaluation.
8. Summary and conclusions
Exploration of the etiology and pathogenesis of MS
has yielded a handful of useful biomarkers. Markers
of both autoimmune and neurodegeneration processes
have been reported. Still, the need for markers for ac-
curate diagnosis, course of severity, likelihood of onset,
and determinants of etiology and pathogenesis are de-
sired. The existence of informative single MS biomark-
ers in such a complex system is not likely. A pattern
of many single molecules that are not useful individu-
ally may hold the key. Our strategy of comprehensive
phenotyping based on discovery rather than hypothe-
sis holds promise for elucidation of such markers. In
addition to these potential benefits, this strategy offers
the researcher an extensive library of new candidate
molecules for support of current theories or develop-
ment of new ideas in the pathophysiology of the dis-
ease. Finally, it must be considered that the molecular
fingerprint of a patient with MS is likely to evolve over
time relative to the underlying pathology. Recognition
and characterization of this alteration will also become
a rich source of information regarding the disease pro-
cess and may yield predictors of various disease pa-
rameters in multiple sclerosis.
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